MOTS-c 40mg

Source: https://pubmed.ncbi.nlm.nih.gov/25738459/

Scientific Findings

Published in Cell Metabolism, this is the landmark study that first identified and characterized MOTS-c. Researchers at the University of Southern California discovered a short open reading frame within mitochondrial DNA encoding a 16 amino acid peptide — which they named MOTS-c — that regulates insulin sensitivity and metabolic homeostasis. The study established that skeletal muscle is MOTS-c's primary target organ, and that its cellular mechanism works by disrupting the folate cycle, causing a build-up of AICAR — a potent natural activator of AMPK, the body's master energy-sensing enzyme. In mouse studies, MOTS-c treatment prevented both age-dependent insulin resistance and high-fat-diet-induced insulin resistance. It also prevented diet-induced obesity without affecting caloric intake, significantly reduced hepatic fat accumulation, and promoted AMPK activation and GLUT4 expression in skeletal muscle. MOTS-c levels in skeletal muscle and circulation were also shown to decline with age in mice, with young mice having measurably higher levels than aged counterparts.

Plain English Summary

This is the founding study of MOTS-c research — the paper that told the scientific world this molecule existed. Its most significant finding was that the mitochondria — long viewed purely as the cell's energy factory — are also capable of producing signaling peptides that regulate how the whole body manages blood sugar and body weight. In plain terms: MOTS-c acts like a natural signal from the mitochondria telling muscles to absorb more glucose and burn more fuel — and that signal weakens with age. The study showed that restoring MOTS-c levels could reverse age-related and diet-induced metabolic decline, positioning it as one of the most novel discoveries in metabolic biology of the past decade.

Source: https://pubmed.ncbi.nlm.nih.gov/33473109/

Scientific Findings

Published in Nature Communications, this study examined whether MOTS-c functions as a mitochondrial-encoded regulator of physical capacity and aging. The researchers tested MOTS-c treatment in mice across three age groups — young (2 months), middle-aged (12 months), and old (22 months) — and measured physical performance on treadmill and rotarod tests. MOTS-c significantly enhanced physical performance in all three age groups compared to untreated controls. In aged mice (the equivalent of 65+ in humans), late-life MOTS-c treatment initiated at 23.5 months and administered three times per week improved grip strength, stride length, and walking speed, and the treated elderly mice were able to outperform untreated middle-aged mice on treadmill tests. The study also confirmed the human relevance of these findings: endogenous MOTS-c levels in skeletal muscle increased nearly 12-fold following exercise in human subjects, and circulating MOTS-c in blood increased by approximately 50% during and after exercise before returning to baseline after rest.

Plain English Summary

This study produced some of the most striking findings in the entire MOTS-c research literature. Elderly mice treated with MOTS-c doubled their running capacity and outperformed untreated mice that were years younger. And in the human arm of the study, exercise was confirmed to directly trigger the body's own production of MOTS-c — establishing it as a genuine exercise-induced signaling molecule. In plain terms: MOTS-c appears to be one of the key biological reasons exercise keeps the body young. When you exercise, your mitochondria produce more MOTS-c, which then drives the metabolic and physical adaptations associated with fitness. This study raised the compelling question of whether supplementing MOTS-c could provide some of the metabolic benefits of exercise — a question researchers continue to investigate.

Source: https://pubmed.ncbi.nlm.nih.gov/27216708/

Scientific Findings

This review published in Free Radical Biology and Medicine by the original MOTS-c research team synthesized the mechanistic understanding of how MOTS-c regulates muscle and fat metabolism at the molecular level. The paper established that MOTS-c's primary metabolic actions target skeletal muscle through AMPK activation — the central energy-sensing pathway — which drives enhanced glucose uptake, improved glycolytic capacity, and increased fatty acid oxidation. The review documented how MOTS-c disrupts the folate-methionine cycle, causing the accumulation of AICAR, which in turn activates AMPK independently of the usual energy-status triggers. It also outlined how MOTS-c is now understood as a "mitochondrial hormone" — a signaling molecule that originates in the mitochondria but acts systemically to regulate metabolism at the whole-organism level. The paper highlighted MOTS-c's functional similarities to metformin — the world's most widely prescribed diabetes drug — in terms of its AMPK-activating, glucose-regulating effects.

Plain English Summary

This paper fills in the "how does it actually work" details behind MOTS-c's metabolic effects. The most striking parallel the authors draw is between MOTS-c and metformin — the first-line diabetes medication. Both work through AMPK activation, both improve glucose metabolism in skeletal muscle, and both appear to share a common downstream pathway. In plain terms, MOTS-c functions like a natural version of one of the most validated metabolic drugs in medicine — except it is produced by your own mitochondria in response to exercise, and its levels decline with age. This mechanistic understanding is what makes MOTS-c one of the most compelling research targets in metabolic and longevity science today.